Log in to your Inderes Free account to see all free content on this page.

Lumito

6.48 SEK

+0.31 %

Less than 1K followers

LUMITO

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+0.31 %

-28.00 %

-7.43 %

-65.89 %

-92.49 %

-94.29 %

-98.07 %

-99.32 %

-97.34 %

Lumito is a Swedish company that develops and markets systems for tissue and biomarker analysis in digital pathology, built on upconverting nanoparticle technology. The company targets healthcare facilities, research and the pharmaceutical sector. The company was formed in 2010 as a spinoff from a research group at Lund University's Department of Atomic Physics and Laser Center. Lumito is headquartered in Lund.

Market cap

22.3M SEK

Turnover

6.46K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

20.2.

2026

Annual report '25

7.5.

2026

General meeting '26

7.5.

2026

Interim report Q1'26

All

Press releases

ShowingAll content types

Regulatory press release13 hours ago

Invitation to webinar in connection with Lumito AB’s year-end report for 2025

Regulatory press release2/3/2026, 8:40 AM

Lumito initiates pilot project with leading professor in urological cancer research at Lund University

Regulatory press release1/30/2026, 2:45 PM

Lumito announces timetable for reverse share split and recalculated terms for outstanding warrants of series TO7

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release1/29/2026, 8:15 AM

Lumito receives patent approval in India

Regulatory press release1/28/2026, 7:30 AM

Two Swedish research customers place orders for Lumito’s SCIZYS Erbium Kit

Regulatory press release1/23/2026, 1:50 PM

Lumito’s technology presented at The Pathological Society of Great Britain & Ireland Winter Meeting 2026

Regulatory press release1/20/2026, 3:30 PM

Changes to the Nomination Committee ahead of Lumito’s Annual General Meeting 2026

Regulatory press release1/13/2026, 8:30 AM

Analyst Group initiates coverage of Lumito

Regulatory press release1/12/2026, 8:15 AM

Lumito receives order from Swedish research unit

Regulatory press release1/8/2026, 12:00 PM

Lumito publishes investor letter – 2025 in review and the road ahead

Regulatory press release12/19/2025, 2:00 PM

The Board of Directors of Lumito proposes a reversed share split

Regulatory press release12/18/2025, 11:15 AM

Lumito’s technology enables quantification of low abundant cells

Regulatory press release12/12/2025, 8:00 AM

Lumito strengthens its international presence and participates in Digital Pathology & AI Congress Europe

Regulatory press release12/11/2025, 9:30 AM

Lumito renews its quality certification, ISO 13485:2016

Regulatory press release12/5/2025, 1:15 PM

Nomination Committee for Lumito appointed ahead of the 2026 Annual General Meeting

Regulatory press release12/2/2025, 7:30 AM

Lumito Appoints Chief Business Officer to accelerate commercial growth

Regulatory press release11/27/2025, 7:30 AM

Lumito AB publishes interim report for the third quarter of 2025

Regulatory press release11/25/2025, 9:00 AM

Invitation to webinar in connection with Lumito AB’s Q3 2025 Interim Report

Regulatory press release11/21/2025, 8:45 AM

Lumito granted SEK 250,000 business development grant from Region Skåne

Regulatory press release11/19/2025, 3:45 PM

Conversion of paid subscribed units (BTUs) and first day of trading in warrants of series TO7

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.